icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
 
 
 
Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART-Naïve HIV+ Patients: Week 48 Results
 
 
  Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
 
Jose M. Gatell1; Francois Raffi2; Andreas Plettenberg3; Don Smith4; Joaquin Portilla5; Christian Hoffmann6; Keikawus Arasteh7; Melanie Thompson8; Xia Xu9; Hedy Teppler9 for the 1439-007 Study Team
1Hospital Clinic/IDIBAPS, University of Barcelona, Barcelona, Spain; 2COREVIH Pays de Loire, France; 3ifi-Institute for Infections, Hamburg, Germany; 4Albion Centre, Sydney, Australia; 5University Miguel Hernandez, Alicante, Spain; 6ICH Study Center, Hamburg, Germany; 7EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 8AIDS Research Consortium of Atlanta, Atlanta, GA, USA; 9Merck & Co., Inc., Kenilworth, NJ, USA

CROI1

CROI2

CROI3

CROI4

CROI5

CROI6

CROI7

CROI8